S&P Futures
4,065.25 -10.25 (-0.25%) Dow Futures
34,002.00 -21.00 (-0.06%) Nasdaq Futures
12,045.25 -61.50 (-0.51%) Russell 2000 Futures
1,907.00 -3.50 (-0.18%) Crude Oil
81.23 +0.22 (+0.27%) Gold
1,928.30 -1.70 (-0.09%)
Acrivon Therapeutics, Inc. (ACRV)
Chart Events
Performance Outlook
| Previous Close | 14.70 |
| Open | 14.72 |
| Bid | 14.25 x 1000 |
| Ask | 14.59 x 800 |
| Day's Range | 13.11 - 14.72 |
| 52 Week Range | 10.90 - 20.70 |
| Volume | |
| Avg. Volume | 42,989 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Insider Monkey
13 Cheap New Stocks To Buy
In this article, we will take a look at the 13 cheap new stocks to buy. To see more such companies, go directly to 5 Cheap New Stocks To Buy. Global markets were rattled by the market crash of 2022 whose reverberations are expected to affect equities for several months to come. However, prudent investors […]
- GlobeNewswire
Acrivon Therapeutics Announces Pricing of Initial Public Offering
WATERTOWN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the pricing of its initial public offering of 7,550,000 shares of common stock at
